Update of the European guidelines for basal cell carcinoma management: Developed by the guideline subcommittee of the European Dermatology Forum

European Journal of Dermatology

Volumn 24, Issue 3, 2014, Pages 312-329

  Trakatelli, Myrto ^a   Morton, Colin ^b   Nagore, Eduardo ^c   Ulrich, Claas ^d   Del Marmol, Veronique ^e   Peris, Ketty ^f   Basset Seguin, Nicole ^g  

^a PAPAGEORGIOU GENERAL HOSPITAL   (Greece)

^b Stirling Royal Infirmary   (United Kingdom)

^c INSTITUTO VALENCIANO DE ONCOLOGÍA   (Spain)

^d CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^e ERASME HOSPITAL   (Belgium)

^f UNIVERSITY OF L'AQUILA   (Italy)

^g SAINT LOUIS HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOQUINOLINE DERIVATIVE; ANTINEOPLASTIC AGENT; IMIQUIMOD;

CARCINOMA, BASAL CELL; HUMAN; PHOTOCHEMOTHERAPY; PRACTICE GUIDELINE; PROCEDURES; SKIN NEOPLASMS; SKIN SURGERY;

AMINOQUINOLINES; ANTINEOPLASTIC AGENTS; CARCINOMA, BASAL CELL; DERMATOLOGIC SURGICAL PROCEDURES; HUMANS; PHOTOCHEMOTHERAPY; SKIN NEOPLASMS;

EID: 84905708146     PISSN: 11671122     EISSN: 19524013     Source Type: Journal    
DOI: 10.1684/ejd.2014.2271     Document Type: Article

References (192)

1. Sterry W. European Dermatology Forum Guideline Committee. Guidelines: the management of basal cell carcinoma. Eur J Dermatol 2006; 16: 467-75.
2. Dandurand M, Petit T, Martel P, Guillot B. Management of basal cell carcinoma in adults: Clinical practice guidelines. Eur J Dermatol 2006; 16: 394-401.
3. Telfer NR, Colver GB, Morton CA. Guidelines for the management of basal cell carcinoma. Br J Dermatol 2008; 159: 35-48.
4. Rubin AI, Chen EH, Ratner D. Basal-cell carcinoma. N Engl J Med 2005; 353: 2262-9.
5. Trakatelli M, Ulrich C, del Marmol V, Euvrard S, Stockfleth E, Abeni D. Epidemiology of nonmelanoma skin cancer (NMSC) in Europe: accurate and comparable data are needed for effective public health monitoring and interventions. Br J Dermatol 2007; 156(Suppl 3): 1-7.
6. Halna JM, Grandadam M, Bueni A. Epidemiologic study of skin cancers from french population (1988-1996). Report of cancer registration of "Haut Rhin" area. Nouv Dermatol 2000; 19: 48-55.
7. Vilar-Coromina N, Miró-Queralt J, Cano-Bautista A, Vilardell-Gil L, Torres Babié P, Marcos-Gragera R. Non-melanoma skin cancer: incidence time trends analysis in Girona, Spain, 1994-2007. Med Clin (Barc) 2011; 137: 145-51.
8. Miller DL, Weinstock MA. Nonmelanoma skin cancer in the United States: incidence. J Am Acad Dermatol 1994; 30(5 Pt 1): 774-8.
9. Birch-Johansen F, Jensen A, Mortensen L, Olesen AB, Kjær SK. Trends in the incidence of non melanoma skin cancer in Denmark 1978-2007: Rapid incidence increase among young Danish women. Int J Cancer 2010; 127: 2190-8.
10. Flohil SC, de Vries E, Neumann HA, Coebergh JW, Nijsten T. Incidence, prevalence and future trends of primary basal cell carcinoma in the Netherlands. Acta Derm Venereol 2011; 91: 24-30.
11. de Vries E, Micallef R, Brewster DH, et al. Population-based estimates of the occurrence of multiple vs first primary basal cell carcinomas in 4 European regions. Arch Dermatol 2012; 148: 347-54.
12. Gallagher RP, Hill GB, Bajdik CD, et al. Sunlight exposure, pigmentary factors, and risk of nonmelanocytic skin cancer. I. Basal cell carcinoma. Arch Dermatol 1995; 131: 157-63.
13. Armstrong BK, Kricker A. The epidemiology of UV induced skin cancer. J Photochem Photobiol 2001; 63: 8-18.
14. Kricker A, Armstrong BK, English DR, Heenan PJ. Does intermittent sun exposure cause basal cell carcinoma? A case-control study in Western Australia. Int J Cancer 1995; 60: 489-94.
15. Rosso S, Zanetti R, Martinez C, et al. The multicentre south European study 'Helios'. II: Different sun exposure patterns in the aetiology of basal cell and squamous cell carcinomas of the skin. Br J Cancer 1996; 73: 1447-54.
16. Iannacone MR, Wang W, Stockwell HG, et al. Patterns and timing of sunlight exposure and risk of basal cell and squamous cell carcinomas of the skin-a case-control study. BMC Cancer 2012; 12: 417.
17. Bauer A, Diepgen TL, Schmitt J. Is occupational solar ultraviolet irradiation a relevant risk factor for basal cell carcinoma? A systematic review and meta-analysis of the epidemiological literature. Br J Dermatol 2011; 165: 612-25.
18. Berg D, Otley CC. Skin cancer in organ transplant recipients: epidemiology, pathogenesis and management. J Am Acad Dermatol 2002; 47: 1-17.
19. Jensen P, Hansen S, Møller B, et al. Skin cancer in kidney and heart transplant recipients and different long-term immunosuppressive therapy regimens. J Am Acad Dermatol 1999; 40(2 Pt 1): 177-86.
20. Wisgerhof HC, Edelbroek JR, de Fijter JW, et al. Subsequent squamous- and basal-cell carcinomas in kidney-transplant recipients after the first skin cancer: cumulative incidence and risk factors. Transplantation 2010; 89: 1231-8.
21. Euvrard S, Kanitakis J, Decullier E, et al. Subsequent skin cancers in kidney and heart transplant recipients after the first squamous cell carcinoma. Transplantation 2006; 81: 1093-100.
22. Johnson RL, Rothman AL, Xie J, et al. Human homolog of patched, a candidate gene for the basal cell nevus syndrome. Science 1996; 272: 1668-71.
23. Teperino R, Amann S, Bayer M, et al. Hedgehog Partial Agonism Drives Warburg-like Metabolism in Muscle and Brown Fat. Cell 2012; 151: 414-26.
24. Knudson AG Jr. Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci USA 1971; 68: 820-3.
25. Pan S, Dong Q, Sun LS, Li TJ. Mechanisms of inactivation of PTCH1 gene in nevoid basal cell carcinoma syndrome: modification of the two-hit hypothesis. Clin Cancer Res 2010; 16: 442-50.
26. Boukamp P. Non-melanoma skin cancer: what drives tumor development and progression? Carcinogenesis 2005; 26: 1657-67.
27. Epstein EH. Basal cell carcinomas: attack of the hedgehog. Nat Rev Cancer 2008; 8: 743-54.
28. Castori M, Morrone A, Kanitakis J, Grammatico P. Genetic skin diseases predisposing to basal cell carcinoma. Eur J Dermatol 2012; 22: 299-309.
29. Liboutet M, Portela M, Delestaing G, et al. MC1R and PTCH gene polymorphism in French patients with basal cell carcinomas. J Invest Dermatol 2006; 126: 1510-7.
30. Stacey SN, Sulem P, Masson G, et al. New common variants affecting susceptibility to basal cell carcinoma. Nat Genet 2009; 41: 909-14.
31. Rizzato C, Scherer D, Rudnai P, et al. POMC and TP53 genetic variability and risk of basal cell carcinoma of skin: interaction between host and genetic factors. J Dermatol Sci 2011; 63: 47-54.
32. Rizzato C, Canzian F, Rudnai P, et al. Interaction between functional polymorphic variants in cytokine genes, established risk factors and susceptibility to basal cell carcinoma of skin. Carcinogenesis 2011; 32: 1849-54.
33. Stacey SN, Gudbjartsson DF, Sulem P, et al. Common variants on 1p36 and 1q42 are associated with cutaneous basal cell carcinoma but not with melanoma or pigmentation traits. Nat Genet 2008; 40: 1313-8.
34. Gudbjartsson DF, Sulem P, Stacey SN, et al. ASIP and TYR pigmentation variants associate with cutaneous melanoma and basal cell carcinoma. Nat Genet 2008; 40: 886-91.
35. Scherer D, Bermejo JL, Rudnai P, et al. MC1R variants associated susceptibility to basal cell carcinoma of skin: interaction with host factors and XRCC3 polymorphism. Int J Cancer 2008; 122: 1787-93.
36. Steding-Jessen M, Birch-Johansen F, Jensen A, Schüz J, Kjær SK, Dalton SO. Socioeconomic status and non-melanoma skin cancer: a nationwide cohort study of incidence and survival in Denmark. Cancer Epidemiol 2010; 34: 689-95.
37. Wang GY, Wang J, Mancianti ML, Epstein EH Jr. Basal cell carcinomas arise from hair follicle stem cells in Ptch1(+/-) mice. Cancer Cell 2011; 19: 114-24.
38. Youssef KK, Van Keymeulen A, Lapouge G, et al. Identification of the cell lineage at the origin of basal cell carcinoma. Nat Cell Biol 2010; 12: 299-305.
39. Ratner D, Lowe L, Johnson TM, Fader DJ. Perineural spread of basal cell carcinomas treated with Mohs micrographic surgery. Cancer 2000; 88: 1605-13.
40. Sexton M, Jones DB, Maloney ME. Histologic pattern analysis of basal cell carcinoma. Study of a series of 1039 consecutive neoplasms. J Am Acad Dermatol 1990; 23(6 Pt 1): 1118-26.
41. Scrivener Y, Grosshans E, Cribier B. Variations of basal cell carcinomas according to gender, age, location and histopathological subtype. Br J Dermatol 2002; 147: 41-7.
42. Altamura D, Menzies SW, Argenziano G, et al. Dermoscopy of basal cell carcinoma: Morphologic variability of global and local features and accuracy of diagnosis. J Am Acad Dermatol 2010; 62: 67-75.
43. Guitera P, Menzies SW, Longo C, Cesinaro AM, Scolyer RA, Pellacani G. In vivo confocal microscopy for diagnosis of melanoma and basal cell carcinoma using a two-step method: analysis of 710 consecutive clinically equivocal cases. J Invest Dermatol 2012; 132: 2386-94.
44. Seidenari S, Arginelli F, Bassoli S, et al. Diagnosis of BCC by multiphoton laser tomography. Skin Res Technol 2013; 19: e297-304.
45. Mogensen M, Joergensen TM, Nürnberg BM, et al. Assessment of optical coherence tomography imaging in the diagnosis of non-melanoma skin cancer and benign lesions versus normal skin: observer-blinded evaluation by dermatologists and pathologists. Dermatol Surg 2009; 35: 965-72.
46. Walling HW, Fosko SW, Geraminejad PA, Whitaker DC, Arpey CJ. Aggressive basal cell carcinoma: presentation, pathogenesis, and management. Cancer Metastasis Rev 2004; 23: 389-402.
47. Bath-Hextall F, Bong J, Perkins W, Williams H. Interventions for basal cell carcinoma of the skin: systematic review. BMJ 2004; 329: 705.
48. Breuninger H, Dietz K. Prediction of subclinical tumor infiltration in basal cell carcinoma. J Dermatol Surg Oncol 1991; 17: 574-8.
49. Batra RS, Kelley LC. Predictors of extensive subclinical spread in nonmelanoma skin cancer treated with Mohs micrographic surgery. Arch Dermatol 2002; 138: 1043-51.
50. Ratner D, Bagiella E. The efficacy of curettage in delineating margins of basal cell carcinoma before Mohs micrographic surgery. Dermatol Surg 2003; 29: 899-903.
51. Ro KW, Seo SH, Son SW, Kim IH. Subclinical infiltration of basal cell carcinoma in asian patients: assessment after mohs micrographic surgery. Ann Dermatol 2011; 23: 276-81.
52. Wolf DJ, Zitelli JA. Surgical margins for basal cell carcinoma. Arch Dermatol 1987; 123: 340-4.
53. Leibovitch I, Huilgol SC, Selva D, Richards S, Paver R. Basal cell carcinoma treated with Mohs surgery in Australia III. Perineural invasion. J Am Acad Dermatol 2005; 53: 458-63.
54. Feasel AM, Brown TJ, Bogle MA, Tschen JA, Nelson BR. Perineural invasion of cutaneous malignancies. Dermatol Surg 2001; 27: 531-42.
55. Kuijpers DIM, Thissen MRTM, Neumann MHA. Basal cell carcinoma: treatment options and prognosis, a scientific approach to a common malignancy. Am J Clin Dermatol 2002; 3: 247-59.
56. Chiller K, Passaro D, McCalmont T, Vin-Christian K. Efficacy of curettage before excision in clearing surgical margins of nonmelanoma skin cancer. Arch Dermatol 2000; 136: 1327-32.
57. Abide JM, Nahai F, Bennett RG. The meaning of surgical margins. Plast Reconstr Surg 1984; 73: 492-7.
58. Gulleth Y, Goldberg N, Silverman RP, Gastman BR. What is the best surgical margin for a Basal cell carcinoma: a meta-analysis of the literature. Plast Reconstr Surg 2010; 126: 1222-31.
59. Walker P, Hill D. Surgical treatment of basal cell carcinomas using standard postoperative histological assessment. Australas J Dermatol 2006; 47: 1-12.
60. Griffiths RW, Suvarna SK, Stone J. Do basal cell carcinomas recur after complete conventional surgical excision? Br J Plast Surg 2005; 58: 795-805.
61. Silverman MK, Kopf AW, Bart RS, Grin CM, Levenstein MS. Recurrence rates of treated basal cell carcinomas. Part 3: Surgical excision. J Dermatol Surg Oncol 1992; 18: 471-6.
62. Rowe DE, Carroll RJ, Day CL Jr. Long-term recurrence rates in previously untreated (primary) basal cell carcinoma: implications for patient follow-up. J Dermatol Surg Oncol 1989; 15: 315-28.
63. Rowe DE, Carroll RJ, Day CL Jr. Mohs surgery is the treatment of choice for recurrent (previously treated) basal cell carcinoma. J Dermatol Surg Oncol 1989; 15: 424-31.
64. Mosterd K, Krekels GAM, Nieman FH, et al. Surgical excision versus Mohs' micrographic surgery for primary and recurrent basalcell carcinoma of the face: a prospective randomised controlled trial with 5-years' follow-up. Lancet Oncol 2008; 9: 1149-56.
65. Kumar P, Orton CI, McWilliam LJ, Watson S. Incidence of incomplete excision in surgically treated basal cell carcinoma: a retrospective clinical audit. Br J Plast Surg 2000; 53: 563-6.
66. Dieu T, Macleod AM. Incomplete excision of basal cell carcinomas: a retrospective audit. ANZ J Surg 2002; 72: 219-21.
67. Nagore E, Grau C, Molinero J, Fortea JM. Positive margins in basal cell carcinoma: relationship to clinical features and recurrence risk. A retrospective study of 248 patients. J Eur Acad Dermatol Venereol 2003; 17: 167-70.
68. De Silva SP, Dellon AL. Recurrence rate of positive margin basal cell carcinoma: results of a five-year prospective study. J Surg Oncol 1985; 28: 72-4.
69. Park AJ, Strick M, Watson JD. Basal cell carcinomas: do they need to be followed up? J R Coll Surg Edinb 1994; 39: 109-11.
70. Sei JF. [Excision limits and reoperation in cutaneous carcinoma]. Ann Dermatol Venereol 1997; 124: 421-6.
71. Wilson AW, Howsam G, Santhanam V, et al. Surgical management of incompletely excised basal cell carcinomas of the head and neck. Br J Oral Maxillofac Surg 2004; 42: 311-4.
72. Menn H, Robins P, Kopf AW, Bart RS. The recurrent basal cell epithelioma. A study of 100 cases of recurrent, re-treated basal cell epitheliomas. Arch Dermatol 1971; 103: 628-31.
73. Angulo J, Serra-Guillén C, Traves V, et al. [Mohs micrographic surgery for repeat excision of basal cell carcinomas on the head with positive margins]. Actas Dermosifiliogr 2011; 102: 797-804.
74. Boulinguez S, Grison-Tabone C, Lamant L, et al. Histological evolution of recurrent basal cell carcinoma and therapeutic implications for incompletely excised lesions. Br J Dermatol 2004; 151: 623-6.
75. Robinson JK, Fisher SG. Recurrent basal cell carcinoma after incomplete resection. Arch Dermatol 2000; 136: 1318-24.
76. Bieley HC, Kirsner RS, Reyes BA, Garland LD. The use of Mohs micrographic surgery for determination of residual tumor in incompletely excised basal cell carcinoma. J Am Acad Dermatol 1992; 26(5 Pt 1): 754-6.
77. Swanson NA. Mohs surgery. Technique, indications, applications, and the future. Arch Dermatol 1983; 119: 761-73.
78. Williford PM, Feldman SR. Surgery for basal-cell carcinoma of the face. Lancet 2004; 364: 1732-3.
79. Emmett AJ. Surgical analysis and biological behaviour of 2277 basal cell carcinomas. ANZ J Surg 1990; 60: 855-63.
80. Miller PK, Roenigk RK, Brodland DG, Randle HW. Cutaneous micrographic surgery: Mohs procedure. Mayo Clin Proc 1992; 67: 971-80.
81. Swanson NA. Mohs surgery. Technique, indications, applications, and the future. Arch Dermatol 1983; 119: 761-73.
82. Smeets NWJ, Kuijpers DIM, Nelemans P, et al. Mohs' micrographic surgery for treatment of basal cell carcinoma of the face-results of a retrospective study and review of the literature. Br J Dermatol 2004; 151: 141-7.
83. Paoli J, Daryoni S, Wennberg AM, et al. 5-year recurrence rates of Mohs micrographic surgery for aggressive and recurrent facial basal cell carcinoma. Acta Derm Venereol 2011; 91: 689-93.
84. Mohs F, Larson P, Iriondo M. Micrographic surgery for the microscopically controlled excision of carcinoma of the external ear. J Am Acad Dermatol 1988; 19: 729-37.
85. Mohs FE. Micrographic surgery for the microscopically controlled excision of eyelid cancers. Arch Ophthalmol 1986; 104: 901-9.
86. Malhotra R, Huilgol SC, Huynh NT, Selva D. The Australian Mohs database, part II: periocular basal cell carcinoma outcome at 5-year follow-up. Ophthalmology 2004; 111: 631-6.
87. Leibovitch I, Huilgol SC, Selva D, Richards S, Paver R. Basal cell carcinoma treated with Mohs surgery in Australia II. Outcome at 5-year follow-up. J Am Acad Dermatol 2005; 53: 452-7.
88. Cook J, Zitelli JA. Mohs micrographic surgery: a cost analysis. J Am Acad Dermatol 1998; 39(5 Pt 1): 698-703.
89. Blázquez-Sánchez N, de Troya-Martín M, Frieyro-Elicegui M, Fúnez-Liébana R, Martín-Márquez L, Rivas-Ruiz F. [Cost analysis of Mohs micrographic surgery in high-risk facial basal cell carcinoma]. Actas Dermosifiliogr 2010; 101: 622-8.
90. Spiller WF, Spiller RF. Treatment of basal cell epithelioma by curettage and electrodesiccation. J Am Acad Dermatol 1984; 11(5 Pt 1): 808-14.
91. Suhge d'Aubermont PC, Bennett RG. Failure of curettage and electrodesiccation for removal of basal cell carcinoma. Arch Dermatol 1984; 120: 1456-60.
92. Kopf AW, Bart RS, Schrager D, Lazar M, Popkin GL. Curettageelectrodesiccation treatment of basal cell carcinomas. Arch Dermatol 1977; 113: 439-43.
93. Chren M-M, Torres JS, Stuart SE, Bertenthal D, Labrador RJ, Boscardin WJ. Recurrence after treatment of nonmelanoma skin cancer: a prospective cohort study. Arch Dermatol 2011; 147: 540-6.
94. Barlow JO, Zalla MJ, Kyle A, DiCaudo DJ, Lim KK, Yiannias JA. Treatment of basal cell carcinoma with curettage alone. J Am Acad Dermatol 2006; 54: 1039-45.
95. Thissen MR, Nieman FH, Ideler AH, Berretty PJ, Neumann HA. Cosmetic results of cryosurgery versus surgical excision for primary uncomplicated basal cell carcinomas of the head and neck. Dermatol Surg 2000; 26: 759-64.
96. Kuflik EG. Cryosurgery for skin cancer: 30-year experience and cure rates. Dermatol Surg 2004; 30(2 Pt 2): 297-300.
97. Hall VL, Leppard BJ, McGill J, Kesseler ME, White JE, Goodwin P. Treatment of basal-cell carcinoma: comparison of radiotherapy and cryotherapy. Clin Radiol 1986; 37: 33-4.
98. Jaramillo-Ayerbe F. Cryosurgery in difficult to treat basal cell carcinoma. Int J Dermatol 2000; 39: 223-9.
99. Tuppurainen K. Cryotherapy for eyelid and periocular basal cell carcinomas: outcome in 166 cases over an 8-year period. Graefes Arch Clin Exp Ophthalmol 1995; 233: 205-8.
100. Nouri K, Chang A, Trent JT, Jiménez GP. Ultrapulse CO2 used for the successful treatment of basal cell carcinomas found in patients with basal cell nevus syndrome. Dermatol Surg 2002; 28: 287-90.
101. Gross K, Kircik L, Kricorian G. 5% fuorouacile cream for the treatment of small superficial basal cell carcinoma: efficacy, cosmetic outcome, and patient satisfaction Dermatol Surg 2007; 33: 433-40.
102. Arits AH, Mosterd K, Essers BA, et al. Photodynamic therapy versus topical imiquimod versus topical fluorouracil for treatment of superficial basal-cell carcinoma: a single blind, non-inferiority, randomised controlled trial. Lancet Oncol 2013; 7: 647-54.
103. Schon MP, Schon M. Imiquimod: mode of action. Br J Dermatol 2007; 157 (suppl 2): 8-13.
104. Wuest M, Dummer R, Urosevic M. Induction of the members of Notch pathway in superfical basal cell carcinomas treated with imiquimod. Arch Dermatol Res 2007; 299: 493-8.
105. Schulze HJ, Cribier B, Requena L, et al. Imiquimod 5% cream for the treatment of superficail basal cell carcinoma: results from a randomized vehicle-controlled study. Br J Dermatol 2005; 152: 939-47.
106. Gollnick H, Barona CG, Frank RG, et al. Recurrence rate of superficial basal cell carcinoma following successful treatment with imiquimod 5% cream: conclusion of a 5 year long term follow up study in Europe. Eur J Dermatol 2008; 18: 677-82.
107. Bath-Hextall FJ, Perkins W, Bong J, Williams HC. Interventions for basal cell carcinoma of the skin. Cochrane Data Syst Rev 2007; CD003412.
108. Geisse J, Caro I, Lindholm J, Golitz I, Stampone P, Owens M. Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from two phase III randomized vehicle controlled studies. J Am Acad Dermatol 2004; 50: 722-33.
109. Sterry W, Ruzicka T, Herrera E, et al. Imiquimod cream 5% cream for the treatment of superficial and nodular basal cell carcinoma: randomized studies comparing low frequency dosing with and without occlusion. Br J Dermatol 2002; 147: 1227-36.
110. Ebell MH, Siwek J, Weiss BD. Strength of recommendation taxonomy (SORT): A patient-centered approach to grading evidence in medical litterature. Am Fam Physician 2004; 69: 548-56.
111. Love E, Bernhard J, Bordeaux J. Topical imiquimod or fluouracil therapy for basal and squamous cell carcinoma-systematic review. Arch Dermatol 2009; 145: 1431-8.
112. Quikck C, Gebauer K, De Ambrosis B, Slacke H, Meng T. Sustained clearance of superficial basal cell carcinomas treated with imiquimod cream 5%: results of a prospective 5-year Study. Cutis 2010; 85: 318-24.
113. Vidal D, Matias-Gulu X, Alomar A. An open study of the efficacy and mechanism of action of topical imiquimod in basal carcinoma. Clin Exp Dermatol 2004; 29: 518-25.
114. Vidal D, Matias-Gulu X, Alomar A. Forty basal cell carcinoma treated with topical imiquimod: outcome 5 years follow up. Arch Dermatol 2007; 143: 266-8.
115. Vanalocha F, Dauden E, Badia X, et al. Cost-effectiveness of treatment of superficial basal cell carcinoma: surgical excision vs. imiquimod 5% cream. Br J Dermatol 2007; 156: 769-71.
116. Basset-Seguin N, Ibbotson SH, Emtestam L, et al. Topical methyl-aminolaevulinate photodynamic therapy versus cryotherapy for superficial basal cell carcinoma: a 5 year randomized trial. Eur J Dermatol 2008; 18: 547-53.
117. Szeimies RM, Ibbotson S, Murrell DF, et al. A clinical study comparing methyl aminolevulinate photodynamic therapy and surgery in small superficial basal cell carcinoma (8-20 mm), with a 12-month follow-up. J Eur Acad Dermatol Venereol 2008; 22: 1302-11.
118. Peng Q, Warloe T, Berg K, et al. 5-Aminolevulinic acid-based photodynamic therapy. Clinical research and future challenges. Cancer 1997; 79: 2282-308.
119. Wang I, Bendsoe N, Klinteberg CA, et al. Photodynamic therapy vs. cryosurgery of basal cell carcinomas: results of a phase III clinical trial. Br J Dermatol 2001; 144: 832-40.
120. Rhodes LE, de Rie M, Enstrom Y, et al. Photodynamic therapy using topical methyl aminolevulinate vs surgery for nodular basal cell carcinoma: results of a multicenter randomized prospective trial. Arch Dermatol 2004; 140: 17-23.
121. Rhodes LE, de Rie MA, Leifsdottir R, et al. Five-year follow-up of a randomized prospective trial of topical methyl aminolevulinatephotodynamic therapy versus surgery for nodular basal cell carcinoma. Arch Dermatol 2007; 143: 1131-6.
122. Foley P, Freeman M, Menter A, et al. Photodynamic therapy with methyl aminolevulinate for primary nodular basal cell carcinoma: results of two randomized studies. Int J Dermatol 2009; 48: 1236-45.
123. Christensen E, Skogvoll E, Viset T, Warloe T, Sundstrøm S. Photodynamic therapy with 5-aminolaevulinic acid, dimethylsulfoxide and curettage in basal cell carcinoma: a 6-year clinical and histological follow-up. J Eur Acad Dermatol Venereol 2009; 23: 58-66.
124. Fantini F, Greco A, Del Giovane C, et al. Photodynamic therapy for basal cell carcinoma: clinical and pathological determinants of response. J Eur Acad Dermatol Venereol 2011; 25: 896-901.
125. Kuijpers D, Thissen MR, Thissen CA, Neumann MH. Similar effectiveness of methyl aminolevulinate and 5-aminolevulinate in topical photodynamic therapy for nodular basal cell carcinoma. J Drugs Dermatol 2006; 5: 642-5.
126. de Haas ER, Kruijt B, Sterenborg HJ, et al. Fractionated illumination significantly improves the response of superficial basal cell carcinoma to aminolevulinic acid photodynamic therapy. J Invest Dermatol 2006; 126: 2679-86.
127. de Haas ER, de Vijlder HC, Sterenborg HJ, et al. Fractionated aminolevulinic acid-photodynamic therapy provides additional evidence for the use of PDT for non-melanoma skin cancer. J Eur Acad Dermatol Venereol 2008; 22: 426-30.
128. Mosterd K, Thissen M, Nelemans P, et al. Fractionated 5- aminolaevulinic acid-photodynamic therapy vs. surgical excision in the treatment of nodular basal cell carcinoma: results of a randomized controlled trial. Br J Dermatol 2008; 159: 864-70.
129. Loncaster J, Swindell R, Slevin F, et al. Efficacy of photodynamic therapy as a treatment for Gorlin Syndrome-related basal cell carcinomas. Clin Oncol 2009; 21: 502-8.
130. Pauwels C, Mazereeuw-Hautier J, Basset-Seguin N, et al. Topical methyl aminolevulinate photodynamic therapy for management of basal cell carcinomas in patients with basal cell nevus syndrome improves patient's satisfaction and reduces the need for surgical procedures. J Eur Acad Dermatol Venereol 2011; 25: 861-4.
131. Schleier P, Hyckel P, Berndt A, et al. Photodynamic therapy of virus-associated epithelial tumours of the face in organ transplant recipients. J Cancer Res Clin Oncol 2004; 130: 279-84.
132. Wulf HC, Pavel S, Stender I, Bakker-Wensveen C. Topical photodynamic therapy for prevention of new skin lesions in renal transplant recipients. Acta Derm Venereol 2006; 86: 25-8.
133. Ibbotson SI. Adverse effects of topical photodynamic therapy. Photoderm Photoimmunol Photomedicine 2011; 27: 116-30.
134. Grapengiesser S, Ericson M, Gudmundsson F, et al. Pain caused by photodynamic therapy of skin cancer. Clin Exp Dermatol 2002; 27: 493-7.
135. Pagliaro J, Elliott T, Bulsara M, et al. Cold air analgesia in photodynamic therapy of basal cell carcinomas and Bowen's disease: an effective addition to treatment: a pilot study. Dermatol Surg 2004; 30: 63-6.
136. Attili SK, Lesar A, McNeill A, et al. An open pilot study of ambulatory photodynamic therapy using a wearable low-irradiance organic light-emitting diode light source in the treatment of nonmelanoma skin cancer. Br J Dermatol 2009; 161: 170-3.
137. Caekelbergh K, Annemans L, Lambert J, Roelands R. Economic evaluation of methyl aminolevulinate photodynamic therapy in the management of actinic keratoses and basal cell carcinoma. Br J Dermatol 2006; 155: 784-90.
138. Annemans L, Roelandts R, Boonen H, et al. Real-life practice study of the clinical outcome and cost-effectiveness of photodynamic therapy using methyl aminolevulinate (MAL-PDT) in the management of actinic keratosis and basal cell carcinoma. Eur J Dermatol 2008; 18: 539-46.
139. Morton CA, MacKie RM, Whitehurst C, et al. Photodynamic therapy for basal cell carcinoma: effect of tumour thickness and duration of photosensitizer application on response. Arch Dermatol 1998; 134: 248-9.
140. Dubin N, Kopf A. Multivariate risk score for recurrence of cutaneous basal cell carcinomas. Arch Dermatol 1983; 119: 373-7.
141. Hall VL, Leppard BJ, McGill J, Kesseler ME, White JE, Goodwin P. Treatment of basal-cell carcinoma: comparison of radiotherapy and cryotherapy. Clin Radiol 1986; 37: 33-4.
142. Rowe DE, Carroll RJ, Day CL Jr. Long-term recurrence rates in previously untreated (primary) basal cell carcinoma: implications for patient follow-up. J Dermatol Surg Oncol 1989; 15: 315-28.
143. Rowe DE, Carroll RJ, Day CL Jr. Mohs surgery is the treatment of choice for recurrent (previously treated) basal cell carcinoma. J Dermatol Surg Oncol 1989; 15: 424-31.
144. Avril MF, Auperin A, Margulis A, et al. Basal cell carcinoma of the face: surgery or radiotherapy? Results of a randomized study. Br J Cancer 1997; 76: 100-6.
145. Silverman MK, Kopf AW, Gladstein AH, Bart RS, Grin CM, Levenstein MJ. Recurrence rates of treated basal cell carcinomas. Part 4: X-ray therapy. J Dermatol Surg Oncol 1992; 18: 549-54.
146. Cooper JS. Radiation therapy for cancers of the skin. Dermatol Clin 1991; 9: 683-7.
147. Orton CI. The treatment of basal cell carcinoma by radiotherapy. Clin Oncol 1978; 4: 317-22.
148. Smith SP, Foley EH, Grande DJ. Use of Mohs micrographic surgery to establish quantitative proof of heightened tumor spread in basal cell carcinoma recurrent following radiotherapy. J Dermatol Surg Oncol 1990; 16: 1012-6.
149. Smith SP, Grande DJ. Basal cell carcinoma recurring after radiotherapy: a unique, difficult treatment subclass of recurrent basal cell carcinoma. J Dermatol Surg Oncol 1991; 17: 26-30.
150. Zagrodnik B, Kempf W, Seifert B, et al. Superficial radiotherapy for patients with basal cell carcinoma: recurrence rates, histologic subtypes, and expression of p53 and Bcl- 2. Cancer 2003; 98: 2708-14.
151. van Hezewijk M, Creutzberg CL, Putter H, et al. Efficacy of a hypofractionated schedule in electron beam radiotherapy for epithelial skin cancer: Analysis of 434 cases. Radiother Oncol 2010; 95: 245-9.
152. Jackson JE, Dickie GJ, Wiltshire KL, et al. Radiotherapy for perineural invasion in cutaneous head and neck carcinomas: toward a risk-adapted treatment approach. Head Neck 2009; 31: 604-10.
153. Wadhera A, Fazio M, Bricca G, Stanton O. Metastatic basal cell carcinoma: a case report and literature review. How accurate is our incidence data? Dermatol Online J 2006; 12: 7.
154. Raszewski RL, Guyuron B. Long-term survival following nodal metastases from basal cell carcinoma. Ann Plast Surg 1990; 24: 170-5.
155. Guthrie TH Jr., Porubsky ES, Luxenberg M, et al. Cisplatin-based chemotherapy in advanced basal and squamous cell carcinomas of the skin: results in 28 patients including 13 patients receiving multimodality therapy. J Clin Oncol 1990; 8: 342-6.
156. Moeholt K, Aagaard H, Pfeiffer P, Hansen O. Platinum-based cytotoxic therapy in basal cell carcinoma - a review of the literature. Acta Oncol 1996; 35: 677-82.
157. Carneiro BA, Watkin WG, Mehta UK, et al. Metastatic basal cell carcinoma: complete response to chemotherapy and associated pure red cell aplasia. Cancer Invest 2006; 24: 396-400.
158. Ganti A, Kessinger A. Systemic therapy for disseminated basal cell carcinoma: An uncommon manifestation of a common cancer. Cancer Treat Rev 2011; 37: 440-3.
159. Von Hoff DD, LoRusso PM, Rudin CM, et al. Inhibition of the hedgehog pathway in advanced basal-cell carcinoma. N Engl J Med 2009; 361: 1164-72.
160. LoRusso PM, Rudin CM, Reddy JC, et al. Phase I trial of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with refractory, locally advanced or metastatic solid tumors. Clin Cancer Res 2011; 17: 2502-11.
161. Sekulic A, Migden MR, Oro AE, et al. Efficacy and safety of vismodegib in advanced basal-cell carcinoma. N Engl J Med 2012; 366: 2171-9.
162. Tang JY, Mackay-Wiggan JM, Aszterbaum M, et al. Inhibiting the hedgehog pathway in patients with the basal-cell nevus syndrome. N Engl J Med 2012; 366: 2180-8.
163. Goldberg LH, Landau JM, Moody MN, Kazakevich N, Holzer AM, Myers A. Resolution of odontogenic keratocysts of the jaw in basal cell nevus syndrome with GDC-0449. Arch Dermatol 2011; 147: 839-41.
164. Anderson L, Schmieder GJ, Werschler WP, et al. Randomized, double-blind, double-dummy, vehicle-controlled study of ingenol mebutate gel 0.025% and 0.05% for actinic keratosis. J Am Acad Dermatol 2009; 60: 934-43.
165. Ramsay JR, Suhrbier A, Aylward JH, et al. The sap from Euphorbia peplus is effective against human nonmelanoma skin cancers. Br J Dermatol 2011; 164: 633-6.
166. Siller G, Rosen R, Freeman M, Welburn P, Katsamas J, Ogbourne SM. PEP005 (ingenol mebutate) gel for the topical treatment of superficial basal cell carcinoma: results of a randomized phase IIa trial. Australas J Dermatol 2010; 51: 99-105.
167. National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology. Basal Cell and Squamous Cell Skin Cancers 2011. http://www.nccn.org/professionals/physician_gls/ pdf/nmsc.pdf (accessed June 3, 2011).
168. Chen J, Ruczinski I, Jorgensen TJ, et al. Nonmelanoma skin cancer and risk for subsequent malignancy. J Natl Cancer Inst 2008; 100: 1215-22.
169. McLoone NM, Tolland J, Walsh M, et al. Follow-up of basal cell carcinomas: an audit of current practice. J Eur Acad Dermatol Venereol 2006; 20: 698-701.
170. Kiiski V, de Vries E, Flohil SC, et al. Risk Factors for Single and Multiple Basal Cell Carcinomas. Arch Dermatol 2010; 146: 848-55.
171. Marcil I, Stern RS. Risk of developing a subsequent nonmelanoma skin cancer in patients with a history of nonmelanoma skin cancer: a critical review of the literature and meta-analysis. Arch Dermatol 2000; 136: 1524-30.
172. van Iersel CA, van de Velden HV, Kusters CD, et al. Prognostic factors for a subsequent basal cell carcinoma: implications for follow up. Br J Dermatol 2005; 153: 1078-80.
173. Lovatt TJ, Lear JT, Bastrilles J, et al. Associations between ultraviolet radiation, basal cell carcinoma site and histology, host characteristics, and rate of development of further tumors. J Am Acad Dermatol 2005; 52(3 Pt 1): 468-73.
174. Silverman MK, Kopf AW, Grin CM, et al. Recurrence rates of treated basal cell carcinomas. Part 2: curettage-electrodesiccation. J Dermatol Surg Oncol 1991; 17: 720-6.
175. Rowe DE, Carroll RJ, Day CL. Long-term recurrence rates in previously untreated (primary) basal cell carcinoma: implications for patient follow-up. J Dermatol Surg Oncol 1989; 15: 315-28.
176. Lin JS, Eder M, Weinmann S, Zuber SP, Beil TL, Plaut D, et al. Behavioral Counseling to Prevent Skin Cancer: Systematic Evidence Review to Update the 2003 U.S. Preventive Services Task Force Recommendation: 2011, Rockville MD.
177. Kutting B, Drexler H. UV-induced skin cancer at workplace and evidence-based prevention. Int Arch Occup Environ Health 2010; 83: 843-54.
178. Corona R, Dogliotti E, D'Errico M, et al. Risk factors for basal cell carcinoma in a Mediterranean population: role of recreational sun exposure early in life. Arch Dermatol 2001; 137: 1162-8.
179. Gon A, Minelli L. Risk factors for basal cell carcinoma in a southern Brazilian population: a case-control study. Int J Dermatol 2011; 50: 1286-90.
180. Grodstein F, Speizer FE, Hunter DJ. A prospective study of incident squamous cell carcinoma of the skin in the nurses' health study. J Natl Cancer Inst 1995; 87: 1061-6.
181. Hunter DJ, Colditz GA, Stampfer MJ, Rosner B, Willett WC, Speizer FE. Risk factors for basal cell carcinoma in a prospective cohort of women. Ann Epidemiol 1990; 1: 13-23.
182. Green A, Battistutta D, Hart V, et al. The Nambour Skin Cancer and Actinic Eye Disease Prevention Trial: design and baseline characteristics of participants. Control Clin Trials 1994; 15: 512-22.
183. Green A, Williams G, Neale R, et al. Daily sunscreen application and betacarotene supplementation in prevention of basal-cell and squamous-cell carcinomas of the skin: a randomised controlled trial. Lancet 1999; 354: 723-9.
184. van der Pols JC, Williams GM, Pandeya N, Logan V, Green AC. Prolonged prevention of squamous cell carcinoma of the skin by regular sunscreen use. Cancer Epidemiol Biomarkers Prev 2006; 15: 2546-8.
185. Kricker A, Armstrong BK, English DR, Heenan PJ. Pigmentary and cutaneous risk factors for non-melanocytic skin cancer-a casecontrol study. Int J Cancer 1991; 48: 650-62.
186. Rosso S, Joris F, Zanetti R. Risk of basal and squamous cell carcinomas of the skin in Sion, Switzerland: a case-control study. Tumori 1999; 85: 435-42.
187. Pandeya N, Purdie DM, Green A, Williams G. Repeated occurrence of basal cell carcinoma of the skin and multifailure survival analysis: follow-up data from Nambour Skin Cancer Prevention Trial. Am J Epidemiol 2005; 161: 748-54.
188. Gordon LG, Scuffham PA, van der Pols JC, McBride P, Williams GM, Green AC. Regular sunscreen use is a cost-effective approach to skin cancer prevention in subtropical settings. J Invest Dermatol 2009; 129: 2766-71.
189. Robinson JK, Rademaker AW. Relative importance of prior basal cell carcinomas, continuing sun exposure, and circulating T lymphocytes on the development of basal cell carcinoma. J Invest Dermatol 1992; 99: 227-31.
190. Bakos RM, Kriz M, Muhlstadt M, Kunte C, Ruzicka T, Berking C. Risk factors for early-onset basal cell carcinoma in a German institution. Eur J Dermatol 2011; 21: 705-9.
191. Ulrich C, Jurgensen JS, Degen A, et al. Prevention of nonmelanoma skin cancer in organ transplant patients by regular use of a sunscreen: a 24 months, prospective, case-control study. Br J Dermatol 2009; 161 (Suppl 3): 78-84.
192. Walther U, Kron M, Sander S, et al. Risk and protective factors for sporadic basal cell carcinoma: results of a two-centre case-control study in southern Germany. Clinical actinic elastosis may be a protective factor. Br J Dermatol 2004; 151: 170-8.